The capital priced semaglutide as a longevity asset beginning in late 2023. SELECT (n=17,604, primary endpoint three-point MACE, HR 0.80 at median 3.3-year follow-up, Novo Nordisk-funded) showed a cardiovascular mortality reduction in adults with established cardiovascular disease and overweight or obesity, a secondary-prevention result in a diseased cohort. The healthy-aging population the longevity thesis requires was not enrolled. No pre-specified biological age endpoint. No all-cause mortality primary. The capital is pricing a longevity thesis. The trial tested a cardiovascular question in sick people.

Neither TGA's Advisory Committee on Medicines nor HSA Singapore's Therapeutic Products Branch has received a longevity or biological-age indication expansion for semaglutide 2.4mg; approved indications in both jurisdictions remain chronic weight management in adults meeting BMI thresholds set at product registration. Extending to a healthy-aging claim requires a dedicated Phase 3 with a biological age endpoint (DNA methylation age, telomere attrition rate, or a validated composite outcome clock) as the pre-specified primary outcome. Novo Nordisk has not filed that programme. APAC family-office positions underwritten as longevity exposures are, in regulatory terms, weight-management positions. HSA Singapore's Therapeutic Products Branch registry listed no indication expansion filing for semaglutide through May 2026.